Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms Compound 13(Dana-Farber Cancer Institute), XY-4-88 |
Target |
Action degraders, inhibitors |
Mechanism KRAS G12C degraders(GTPase KRas G12C degraders), KRAS G12C inhibitors(GTPase KRas G12C inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC48H50ClFN10O6 |
InChIKeyHIBGKXYCBQYVSE-UHFFFAOYSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 26 Dec 2019 |